KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CareDx (CDNA) Cash & Equivalents (2016 - 2025)

CareDx (CDNA) has disclosed Cash & Equivalents for 13 consecutive years, with $65.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 42.95% to $65.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $65.4 million through Dec 2025, down 42.95% year-over-year, with the annual reading at $65.4 million for FY2025, 42.95% down from the prior year.
  • Cash & Equivalents hit $65.4 million in Q4 2025 for CareDx, down from $91.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $353.1 million in Q3 2021 to a low of $65.4 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $144.6 million across 5 years, with a median of $92.4 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: soared 860.9% in 2021 and later tumbled 76.5% in 2022.
  • Year by year, Cash & Equivalents stood at $348.5 million in 2021, then crashed by 74.2% to $89.9 million in 2022, then fell by 8.59% to $82.2 million in 2023, then surged by 39.53% to $114.7 million in 2024, then crashed by 42.95% to $65.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for CDNA at $65.4 million in Q4 2025, $91.4 million in Q3 2025, and $68.2 million in Q2 2025.